[go: up one dir, main page]

SE9604793D0 - New polymorphs - Google Patents

New polymorphs

Info

Publication number
SE9604793D0
SE9604793D0 SE9604793A SE9604793A SE9604793D0 SE 9604793 D0 SE9604793 D0 SE 9604793D0 SE 9604793 A SE9604793 A SE 9604793A SE 9604793 A SE9604793 A SE 9604793A SE 9604793 D0 SE9604793 D0 SE 9604793D0
Authority
SE
Sweden
Prior art keywords
pct
omeprazole
sec
date
new polymorphs
Prior art date
Application number
SE9604793A
Other languages
English (en)
Other versions
SE9604793L (sv
SE510666C2 (sv
Inventor
Martin Bohlin
Karol Horvath
Sverker Von Unge
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20405146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9604793(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9604793A priority Critical patent/SE510666C2/sv
Publication of SE9604793D0 publication Critical patent/SE9604793D0/sv
Priority to TW086118449A priority patent/TW538039B/zh
Priority to ZA9711046A priority patent/ZA9711046B/xx
Priority to YUP-281/99A priority patent/RS49685B/sr
Priority to PCT/SE1997/002125 priority patent/WO1998028294A1/en
Priority to AT97951367T priority patent/ATE236898T1/de
Priority to IDW990483A priority patent/ID21850A/id
Priority to HU0001547A priority patent/HU227589B1/hu
Priority to AU55026/98A priority patent/AU730129B2/en
Priority to US09/000,154 priority patent/US6162816A/en
Priority to EEP199900259A priority patent/EE03923B1/xx
Priority to RU99116303/04A priority patent/RU2184734C2/ru
Priority to TR1999/01410T priority patent/TR199901410T2/xx
Priority to DE69720774T priority patent/DE69720774T2/de
Priority to PL97334297A priority patent/PL190377B1/pl
Priority to BR9714059-7A priority patent/BR9714059A/pt
Priority to PT97951367T priority patent/PT946547E/pt
Priority to CA002274076A priority patent/CA2274076C/en
Priority to ES97951367T priority patent/ES2194231T3/es
Priority to UA99073869A priority patent/UA55436C2/uk
Priority to CN97180849A priority patent/CN1109684C/zh
Priority to JP52868598A priority patent/JP4402174B2/ja
Priority to KR1019997005574A priority patent/KR20000069595A/ko
Priority to IL13045097A priority patent/IL130450A0/xx
Priority to SK765-99A priority patent/SK285151B6/sk
Priority to DK97951367T priority patent/DK0946547T3/da
Priority to CZ19992202A priority patent/CZ294784B6/cs
Priority to EP97951367A priority patent/EP0946547B1/en
Priority to ARP970105920A priority patent/AR010361A1/es
Priority to SI9730528T priority patent/SI0946547T1/xx
Priority to NZ336024A priority patent/NZ336024A/en
Priority to MYPI97006176A priority patent/MY117032A/en
Priority to EG136097A priority patent/EG24414A/xx
Priority to SA97180739A priority patent/SA97180739B1/ar
Publication of SE9604793L publication Critical patent/SE9604793L/sv
Priority to IS5070A priority patent/IS1981B/is
Publication of SE510666C2 publication Critical patent/SE510666C2/sv
Priority to NO19993068A priority patent/NO317191B1/no
Priority to HK00101986A priority patent/HK1022909A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE9604793A 1996-12-20 1996-12-20 Nya Kristallmodifikationer SE510666C2 (sv)

Priority Applications (37)

Application Number Priority Date Filing Date Title
SE9604793A SE510666C2 (sv) 1996-12-20 1996-12-20 Nya Kristallmodifikationer
TW086118449A TW538039B (en) 1996-12-20 1997-12-08 Neutral S-omeprazole in a form or b form, process for preparing the same, and pharmaceutical composition comprising the same
ZA9711046A ZA9711046B (en) 1996-12-20 1997-12-09 A novel compound form.
SI9730528T SI0946547T1 (en) 1996-12-20 1997-12-16 A novel compound form
NZ336024A NZ336024A (en) 1996-12-20 1997-12-16 Neutral crystalline S-omeprazole
CA002274076A CA2274076C (en) 1996-12-20 1997-12-16 Crystalline form of s-omeprazole
CN97180849A CN1109684C (zh) 1996-12-20 1997-12-16 新的化合物形态
AT97951367T ATE236898T1 (de) 1996-12-20 1997-12-16 S-omeprazol in festform
IDW990483A ID21850A (id) 1996-12-20 1997-12-16 Formula senyawa baru
HU0001547A HU227589B1 (en) 1996-12-20 1997-12-16 Crystal form of (s)-omeprazole
AU55026/98A AU730129B2 (en) 1996-12-20 1997-12-16 A novel compound form
US09/000,154 US6162816A (en) 1996-12-20 1997-12-16 Crystalline form of the S-enantiomer of omeprazole
EEP199900259A EE03923B1 (et) 1996-12-20 1997-12-16 S-omeprasool neutraalsel kujul, selle valmistamise protsess ja seda sisaldavad ravimsegud
RU99116303/04A RU2184734C2 (ru) 1996-12-20 1997-12-16 S-омепразол в нейтральной форме, способы его получения, фармацевтическая композиция, содержащая s-омепразол в нейтральной форме, и способ лечения связанного с желудочной кислотой состояния
TR1999/01410T TR199901410T2 (xx) 1996-12-20 1997-12-16 Yeni bir bile�im bi�imi.
DE69720774T DE69720774T2 (de) 1996-12-20 1997-12-16 S-omeprazol in festform
PL97334297A PL190377B1 (pl) 1996-12-20 1997-12-16 S-Omeprazol w postaci obojętnej, sposób wytwarzania S-omeprazolu, środek farmaceutyczny i zastosowanie S-omeprazolu
BR9714059-7A BR9714059A (pt) 1996-12-20 1997-12-16 S-omeprazol em uma forma neutra, processo para preparar o mesmo, uso deste, composição farmacêutica, e, processo para tratar uma condição relacionada com ácido gástrico.
PT97951367T PT946547E (pt) 1996-12-20 1997-12-16 Nova forma de composto
YUP-281/99A RS49685B (sr) 1996-12-20 1997-12-16 Novi oblik jedinjenja
ES97951367T ES2194231T3 (es) 1996-12-20 1997-12-16 Una nueva forma de compuesto.
UA99073869A UA55436C2 (uk) 1996-12-20 1997-12-16 Нова форма s-омепразолу, спосіб його одержання, фармацевтична композиція та використання у виробництві лікувального засобу
PCT/SE1997/002125 WO1998028294A1 (en) 1996-12-20 1997-12-16 A novel compound form
JP52868598A JP4402174B2 (ja) 1996-12-20 1997-12-16 新規な化合物形態
KR1019997005574A KR20000069595A (ko) 1996-12-20 1997-12-16 신규한 형태의 화합물
IL13045097A IL130450A0 (en) 1996-12-20 1997-12-16 A novel compound form
SK765-99A SK285151B6 (sk) 1996-12-20 1997-12-16 Neutrálna forma S-enantioméru omeprazolu, spôsob jeho prípravy, farmaceutická kompozícia s jeho obsahom a jeho použitie
DK97951367T DK0946547T3 (da) 1996-12-20 1997-12-16 Hidtil ukendt forbindelsesform
CZ19992202A CZ294784B6 (cs) 1996-12-20 1997-12-16 Nová forma S-omeprazolu
EP97951367A EP0946547B1 (en) 1996-12-20 1997-12-16 A novel compound form
ARP970105920A AR010361A1 (es) 1996-12-20 1997-12-16 "S-OMEPRAZOL [ENANTIoMERO S DE 5-METOXI-2-[[(4--METOXI-3,5-DIMETIL-2-PIRIDINIL)-METIL]SULFINIL]-1H-BENCIMIDAZOL], EN UNA FORMA NEUTRA NO SALINA, PROCESO PARA SU PREPARACION, COMPOSICION FARMACEUTICA, Y SU USO PARA LA MANUFACTURA DE MEDICAMENTOS"
MYPI97006176A MY117032A (en) 1996-12-20 1997-12-19 A novel compound form.
EG136097A EG24414A (en) 1996-12-20 1997-12-20 A novel compound form
SA97180739A SA97180739B1 (ar) 1996-12-20 1997-12-27 الشكل البللوري للمتشاكل S - enantiomer للأومبرازول omeprazole
IS5070A IS1981B (is) 1996-12-20 1999-06-07 Nýtt form S-handhverfu ómeprasóls og lyfjablöndursem innihalda það
NO19993068A NO317191B1 (no) 1996-12-20 1999-06-21 S-omeprazol i noytral form, fremgangsmate for fremstilling derav, farmasoytisk preparat inneholdende en slik form, og anvendelse derav
HK00101986A HK1022909A1 (en) 1996-12-20 2000-03-31 A novel compound form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9604793A SE510666C2 (sv) 1996-12-20 1996-12-20 Nya Kristallmodifikationer

Publications (3)

Publication Number Publication Date
SE9604793D0 true SE9604793D0 (sv) 1996-12-20
SE9604793L SE9604793L (sv) 1998-06-21
SE510666C2 SE510666C2 (sv) 1999-06-14

Family

ID=20405146

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9604793A SE510666C2 (sv) 1996-12-20 1996-12-20 Nya Kristallmodifikationer

Country Status (37)

Country Link
US (1) US6162816A (sv)
EP (1) EP0946547B1 (sv)
JP (1) JP4402174B2 (sv)
KR (1) KR20000069595A (sv)
CN (1) CN1109684C (sv)
AR (1) AR010361A1 (sv)
AT (1) ATE236898T1 (sv)
AU (1) AU730129B2 (sv)
BR (1) BR9714059A (sv)
CA (1) CA2274076C (sv)
CZ (1) CZ294784B6 (sv)
DE (1) DE69720774T2 (sv)
DK (1) DK0946547T3 (sv)
EE (1) EE03923B1 (sv)
EG (1) EG24414A (sv)
ES (1) ES2194231T3 (sv)
HK (1) HK1022909A1 (sv)
HU (1) HU227589B1 (sv)
ID (1) ID21850A (sv)
IL (1) IL130450A0 (sv)
IS (1) IS1981B (sv)
MY (1) MY117032A (sv)
NO (1) NO317191B1 (sv)
NZ (1) NZ336024A (sv)
PL (1) PL190377B1 (sv)
PT (1) PT946547E (sv)
RS (1) RS49685B (sv)
RU (1) RU2184734C2 (sv)
SA (1) SA97180739B1 (sv)
SE (1) SE510666C2 (sv)
SI (1) SI0946547T1 (sv)
SK (1) SK285151B6 (sv)
TR (1) TR199901410T2 (sv)
TW (1) TW538039B (sv)
UA (1) UA55436C2 (sv)
WO (1) WO1998028294A1 (sv)
ZA (1) ZA9711046B (sv)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SI20019A (sl) 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
IL142703A (en) 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
JP3926936B2 (ja) 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
SE9804003D0 (sv) 1998-11-23 1998-11-23 Astra Ab A method of producing drug particles
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
JP2000344739A (ja) * 1999-06-01 2000-12-12 Sumitomo Chem Co Ltd Ｎ−保護−アゼチジン−２−カルボン酸の製造方法
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
DE60131649T2 (de) 2000-05-15 2008-10-30 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung eines kristalls
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
WO2002012225A1 (fr) 2000-08-04 2002-02-14 Takeda Chemical Industries, Ltd. Sels de composé à base de benzimidazole et leurs applications
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
EP2163241A1 (en) 2001-06-01 2010-03-17 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB2376231A (en) 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
CN100378093C (zh) * 2002-06-27 2008-04-02 雷迪实验室有限公司 一种制备包括无定形艾美拉唑及其盐在内的光学纯或光学浓缩的亚砜化合物的方法
US7169793B2 (en) 2002-06-27 2007-01-30 Dr. Reddy's Laboratories Limited Process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
AU2003262992A1 (en) * 2002-08-30 2004-03-19 Reddy's Laboratories Limited Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
EP2596791B1 (en) 2002-10-16 2015-04-01 Takeda Pharmaceutical Company Limited Stable solid preparations
WO2004037253A1 (en) * 2002-10-22 2004-05-06 Ranbaxy Laboratories Limited Amorphous form of esomeprazole salts
US20040242642A1 (en) * 2002-11-18 2004-12-02 Dr. Reddy's Laboratories Limited Crystalline esomeprazole compounds and process for the preparation thereof
CA2517714A1 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Polymorphs of s-omeprazole
CA2516600C (en) * 2003-03-24 2011-04-05 Eisai Co., Ltd. Process for production of sulfoxide proton pump inhibitors in the amorphous state
CN1842525A (zh) * 2003-05-05 2006-10-04 兰贝克赛实验室有限公司 苯并咪唑衍生物的钡盐
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SE0400410D0 (sv) 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
MXPA06015031A (es) 2004-06-24 2007-02-08 Astrazeneca Ab Nuevo proceso para la preparacion de modificaciones cristalinas para usarse en la preparacion de sal de sodio de esomeprazol.
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
RU2007145207A (ru) * 2005-05-06 2009-06-20 Гленмарк Фармасьютикалз Лимитед (In) Стронциваемая соль эзомепразола, способ ее получения и содержащее ее фармацевтические композиции
WO2006131338A2 (en) * 2005-06-08 2006-12-14 Lek Pharmaceuticals D.D. Crystalline solvate of omeprazole sodium
EP1891043A1 (en) 2005-06-15 2008-02-27 Hetero Drugs Limited Amorphous esomeprazole hydrate
NL2000126C2 (nl) * 2005-07-15 2008-01-29 Solvay Werkwijze voor de vervaardiging van eptifibatide.
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
US20090082572A1 (en) * 2005-11-14 2009-03-26 Hetero Drugs Limited Process for amorphous esomeprazole
CA2631919A1 (en) * 2005-12-05 2007-06-14 Astrazeneca Ab New process for the preparation of esomeprazole non-salt form
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
ES2325336T3 (es) 2005-12-28 2009-09-01 Union Quimico-Farmaceutica, S.A. Procedimiento para la preparacion del enantiomero (s) de omeprazol.
EP2000468A1 (en) * 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
WO2009047775A2 (en) * 2007-10-08 2009-04-16 Hetero Drugs Limited Polymorphs of esomeprazole salts
TWI447110B (zh) 2008-03-10 2014-08-01 Takeda Pharmaceutical 苯并咪唑化合物之結晶
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
BRPI0918492A2 (pt) 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
WO2010151216A1 (en) 2009-06-25 2010-12-29 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
EP2510089B1 (en) 2009-12-08 2015-10-21 Codexis, Inc. Synthesis of prazole compounds
HUE037616T2 (hu) 2010-12-08 2018-09-28 Codexis Inc Biokatalizátorok és eljárások armodafinil szintéziséhez
WO2013101897A2 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
RU2501549C1 (ru) 2012-08-30 2013-12-20 Авва Девелопмент Лтд Фармацевтическая композиция для лечения гастроэзофагеальной рефлюксной болезни
CN107043367A (zh) * 2017-05-26 2017-08-15 重庆莱美隆宇药业有限公司 一种中性s‑奥美拉唑的干燥工艺
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
PT723436E (pt) * 1994-07-08 2002-02-28 Astrazeneca Ab Forma de dosagem em comprimidos com unidades multiplas

Also Published As

Publication number Publication date
ID21850A (id) 1999-08-05
SK285151B6 (sk) 2006-07-07
JP2001507025A (ja) 2001-05-29
NO993068L (no) 1999-06-21
CZ294784B6 (cs) 2005-03-16
US6162816A (en) 2000-12-19
EE03923B1 (et) 2002-12-16
PL334297A1 (en) 2000-02-14
HK1022909A1 (en) 2000-08-25
IL130450A0 (en) 2000-06-01
SK76599A3 (en) 1999-12-10
DE69720774T2 (de) 2004-02-05
IS5070A (is) 1999-06-07
SI0946547T1 (en) 2003-10-31
SE9604793L (sv) 1998-06-21
SE510666C2 (sv) 1999-06-14
CN1109684C (zh) 2003-05-28
CA2274076C (en) 2008-09-30
YU28199A (sh) 2002-03-18
IS1981B (is) 2005-01-14
AU730129B2 (en) 2001-02-22
ZA9711046B (en) 1998-06-22
UA55436C2 (uk) 2003-04-15
WO1998028294A1 (en) 1998-07-02
HU0001547D0 (sv) 2002-05-29
TR199901410T2 (xx) 1999-08-23
ATE236898T1 (de) 2003-04-15
CA2274076A1 (en) 1998-07-02
RS49685B (sr) 2007-11-15
EP0946547B1 (en) 2003-04-09
EG24414A (en) 2009-05-25
AR010361A1 (es) 2000-06-07
BR9714059A (pt) 2000-05-09
PL190377B1 (pl) 2005-12-30
DK0946547T3 (da) 2003-06-30
PT946547E (pt) 2003-07-31
TW538039B (en) 2003-06-21
ES2194231T3 (es) 2003-11-16
JP4402174B2 (ja) 2010-01-20
EE9900259A (et) 2000-02-15
DE69720774D1 (de) 2003-05-15
KR20000069595A (ko) 2000-11-25
CZ220299A3 (cs) 2000-02-16
HU227589B1 (en) 2011-09-28
NO317191B1 (no) 2004-09-13
SA97180739B1 (ar) 2006-05-20
CN1241183A (zh) 2000-01-12
NZ336024A (en) 2001-02-23
NO993068D0 (no) 1999-06-21
HUP0001547A2 (hu) 2002-05-29
HUP0001547A3 (en) 2002-06-28
MY117032A (en) 2004-04-30
AU5502698A (en) 1998-07-17
RU2184734C2 (ru) 2002-07-10
EP0946547A1 (en) 1999-10-06

Similar Documents

Publication Publication Date Title
SE9604793D0 (sv) New polymorphs
DE60009511D1 (de) Nematizide trifluorbutene
FI974368A0 (sv) Dipeptider vilka främjar frigöring av tillväxthormon
ATE235826T1 (de) Verwendung einer mischung enthaltend emulgatore, komplexbildern und etherische öle als desinfektionsmittel
NO954320D0 (no) Lyosfærer omfattende gonadotropin
DE69528829D1 (de) Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
FI971967A0 (sv) Användning av dioxomorfoliner för att bekämpa endoparasiter, nya dioxomorfoliner och förfarande för deras framställning
BR9809185A (pt) Diidropiranos fundidos
FI972703A0 (sv) Rekombinat IL-5-antagonister användbara vid behandling av IL-5-relaterade sjukdomar
DK0989973T3 (da) Chalconer med antiproliferativ aktivitet
GB9126725D0 (en) Process
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
ID28119A (id) Pati yang dimodifikasi stabil-garam
EA199800993A1 (ru) Композиции, содержащие фосфатидные кислоты
ATE215525T1 (de) Stabile derivate von ubiquinol, verfahren zu ihrer herstellung und ihre pharmazeutische anwendung
NO970341D0 (no) Imidazopyridin-azolidinoner
ATE215941T1 (de) Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
DE59409983D1 (de) Pyridiniumsalze und ihre verwendung zur bekämpfung von helicobacter-bakterien
ATE183100T1 (de) Neuartige glukohydrolase-inhibitoren nützlich als antidiabetische, antivirale und antimetastatische mittel
DE69930952D1 (de) Gesteuerte freisetzung von antidepressiva
MX9704035A (es) 1,1-dioxidos de 2-(fosfiniloximetil)-1,2,5-tiadiazolidin-3-ona substituidos y composiciones y metodo de uso de los mismos.
SE9404438D0 (sv) New process
MX9704036A (es) 1,1-dioxidos y composiciones de 2-(2,3,5,6-tetrafluoro-4-piridil)-1,2,5-thiadizaolidin-3-ona y metodo de uso.
ZA200103910B (en) 1,4-Diaryl-2-fluoro-1-buten-3-ol compounds and their use in the preparation of 1,4-diaryl-2-fluoro-1,3-butadiene and 1,4-diaryl-2-fluoro-2-butene compounds.